Clinical Trial Update: Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update comparing sacituzumab govitecan with bevacizumab to standard chemotherapy for recurrent platinum-sensitive ovarian, fallopian tube…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Avastin (bevacizumab)
• CARBOPLATIN (Carboplatin)
• Doxil (liposomal doxorubicin)
• TRODELVY (sacituzumab govitecan)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma | Phase 2 | Status: NOT_YET_RECRUITING